PH12022553501A1 - Alk2 inhibitors for the treatment of anemia - Google Patents

Alk2 inhibitors for the treatment of anemia

Info

Publication number
PH12022553501A1
PH12022553501A1 PH1/2022/553501A PH12022553501A PH12022553501A1 PH 12022553501 A1 PH12022553501 A1 PH 12022553501A1 PH 12022553501 A PH12022553501 A PH 12022553501A PH 12022553501 A1 PH12022553501 A1 PH 12022553501A1
Authority
PH
Philippines
Prior art keywords
anemia
treatment
alk2 inhibitors
alk2
inhibitors
Prior art date
Application number
PH1/2022/553501A
Other languages
English (en)
Inventor
Ekaterine Asatiani
Yaoyu Chen
Francis Sã‰Guy
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of PH12022553501A1 publication Critical patent/PH12022553501A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
PH1/2022/553501A 2020-06-16 2021-06-15 Alk2 inhibitors for the treatment of anemia PH12022553501A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063039742P 2020-06-16 2020-06-16
US202063056761P 2020-07-27 2020-07-27
US202163152516P 2021-02-23 2021-02-23
PCT/US2021/037377 WO2021257532A1 (en) 2020-06-16 2021-06-15 Alk2 inhibitors for the treatment of anemia

Publications (1)

Publication Number Publication Date
PH12022553501A1 true PH12022553501A1 (en) 2024-04-22

Family

ID=76845323

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/553501A PH12022553501A1 (en) 2020-06-16 2021-06-15 Alk2 inhibitors for the treatment of anemia

Country Status (13)

Country Link
US (2) US11723899B2 (https=)
EP (1) EP4164641A1 (https=)
JP (1) JP2023530316A (https=)
KR (1) KR20230025444A (https=)
CN (1) CN115968289B (https=)
AU (1) AU2021292484A1 (https=)
CA (1) CA3187767A1 (https=)
CL (2) CL2022003511A1 (https=)
IL (1) IL298767A (https=)
MX (1) MX2022015900A (https=)
PH (1) PH12022553501A1 (https=)
TW (1) TW202214239A (https=)
WO (1) WO2021257532A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113366019B (zh) 2018-10-23 2024-08-27 科乐斯疗法公司 Alk2抗体及其使用方法
JP7717065B2 (ja) 2019-11-22 2025-08-01 インサイト コーポレーション Ａｌｋ２阻害剤及びｊａｋ２阻害剤を含む併用療法
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2021257532A1 (en) 2020-06-16 2021-12-23 Incyte Corporation Alk2 inhibitors for the treatment of anemia
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
US20250282877A1 (en) * 2021-05-11 2025-09-11 Keros Therapeutics, Inc. Methods of using alk2 and alk3 antibodies
WO2023198114A1 (zh) * 2022-04-13 2023-10-19 杭州邦顺制药有限公司 Alk2激酶抑制剂

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077290A (en) 1990-10-11 1991-12-31 Merck & Co., Inc. Morpholine derivatives compositions and use
TW530054B (en) 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
EP1501514B1 (en) 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
US20040067985A1 (en) 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
SE0203753D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
WO2004092727A2 (en) 2003-04-11 2004-10-28 Structural Genomix, Inc. Compound libraries and methods for drug discovery
AU2005247699A1 (en) 2004-05-27 2005-12-08 Pfizer Inc. Aminopyridine derivatives as selective dopamine D3 agonists
SA05260265A (ar) 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
BRPI0607913A2 (pt) 2005-04-08 2010-03-23 Eisai R&D Man Co Ltd agente terapÊutico para discinesia
WO2007011760A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
PE20071241A1 (es) 2006-01-17 2008-01-14 Schering Corp Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios
CA2658362A1 (en) 2006-06-29 2008-01-03 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors
CA2727174A1 (en) 2008-06-20 2010-01-21 Jiangao Song Aryl gpr119 agonists and uses thereof
US8987271B2 (en) 2010-12-22 2015-03-24 Eutropics Pharmaceuticals, Inc. 2,2′-biphenazine compounds and methods useful for treating disease
LT2714677T (lt) 2011-05-23 2018-12-10 Merck Patent Gmbh Piridino ir pirazino dariniai
CN108484449A (zh) 2011-09-09 2018-09-04 蓝瑟斯医学影像公司 用于合成和使用显像剂的组合物、方法和系统
JP6430383B2 (ja) 2012-09-28 2018-11-28 ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ 選択的ｂｍｐ阻害剤としての縮合複素環化合物
EP2964651A4 (en) 2013-03-04 2016-11-30 Brigham & Womens Hospital BMP HEMMER AND METHOD OF USE THEREOF
MX394360B (es) 2013-03-14 2025-03-24 Sumitomo Pharma Oncology Inc Inhibidores de jak2 y alk2 y metodos para su uso.
BR112016008632A8 (pt) 2013-10-21 2020-03-17 Merck Patent Gmbh compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica
NZ734082A (en) 2015-01-20 2019-01-25 Boehringer Ingelheim Animal Health Usa Inc Anthelmintic compounds, compositions and method of using thereof
PE20181017A1 (es) 2015-08-31 2018-06-26 Dong A Socio Holdings Co Ltd Compuestos heteroarilo y su uso como farmacos terapeuticos
MX388518B (es) * 2016-07-20 2025-03-19 Novartis Ag Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2.
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
EP4041243A4 (en) 2019-09-27 2023-10-18 Disc Medicine, Inc. METHODS OF TREATMENT OF ANEMIA OF CHRONIC DISEASE
JP7717065B2 (ja) * 2019-11-22 2025-08-01 インサイト コーポレーション Ａｌｋ２阻害剤及びｊａｋ２阻害剤を含む併用療法
WO2021257532A1 (en) 2020-06-16 2021-12-23 Incyte Corporation Alk2 inhibitors for the treatment of anemia

Also Published As

Publication number Publication date
JP2023530316A (ja) 2023-07-14
AU2021292484A1 (en) 2023-01-19
US11723899B2 (en) 2023-08-15
MX2022015900A (es) 2023-01-24
CN115968289A (zh) 2023-04-14
US20210393605A1 (en) 2021-12-23
WO2021257532A1 (en) 2021-12-23
CA3187767A1 (en) 2021-12-23
CN115968289B (zh) 2025-09-30
KR20230025444A (ko) 2023-02-21
CL2023001952A1 (es) 2023-12-15
US12383541B2 (en) 2025-08-12
EP4164641A1 (en) 2023-04-19
CL2022003511A1 (es) 2023-06-02
TW202214239A (zh) 2022-04-16
IL298767A (en) 2023-02-01
US20230338352A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
PH12022553501A1 (en) Alk2 inhibitors for the treatment of anemia
MX2024000271A (es) Inhibidor de shp2 y uso del mismo.
MX2024004215A (es) Terapias combinadas de inhibidores de kras g12d con inhibidores de sos1.
EA202190630A1 (ru) Способы комбинированной терапии
ZA202300875B (en) Kat6 inhibitor methods and combinations for cancer treatment
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
MX2021009269A (es) Inhibidores de enpp1 y metodos para modular una respuesta inmunitaria.
MX2024014500A (es) Inhibidores piridinicos de la cinasa 1 de puntos de regulacion (chk1) y usos de estos
PH12019502132A1 (en) Combination therapy for the treatment or prevention of tumours
MX2023007193A (es) Inhibidores de enpp1 y su uso para el tratamiento del cancer.
EA202192528A1 (ru) Комбинация ингибиторов pd-1 и ингибиторов lag-3 для повышения эффективности при лечении рака
MX2018014435A (es) Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer.
EP4512480A3 (en) Cancer treatments using combinations of cdk and erk inhibitors
MX2024004213A (es) Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados.
MX2025003908A (es) Compuesto inhibidor de parg
MX2024004214A (es) Combinaciones de inhibidores de kras g12d con irinotecán y métodos de tratamiento relacionados.
MX2016002479A (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris.
MX2022011725A (es) Metodos para tratar una lesion pulmonar con inhibidores de cgrp.
MX2024006678A (es) Inhibidor de cdk4 para el tratamiento del cancer.
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
MX2024014121A (es) Metodos y composiciones para el tratamiento del exceso de glucocorticoides
MX2022007113A (es) Inhibidores de la desmetilasa de la histona especifica de la lisina para el tratamiento de las neoplasias mieloproliferativas.
MX2021002590A (es) Metodos de uso de un compuesto de fenoxipropilamina para tratar el dolor.
WO2020005869A3 (en) Compositions and methods for the treatment of cancer characterized with pcsk9 expression
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.